Support LinksChrome Firefox Safari Edge View Versions © 2025 Advarra, Inc.

To search for a clinical trial (protocol), use any or all of the search fields: Select from drop down lists or type search criteria in any of the text fields. Browse by Physician or Drug, use the …

SIP Version 14.0.0.010 Copyright © 2001-2020 Forte Research Systems, Inc. all rights reserved.

Inclusion Criteria Inclusion Criteria Male or female subject aged >= 18 years.Histologically confirmed urothelial carcinoma with metastatic disease or with unresectable, locally advanced …

Objectives The objectives of this study is to evaluate the efficacy and safety of IMMU-132 in previously treated metastatic urothelial cancers.

To compare between arms patient-reported urinary function and urinary bother over time (after initiation of SST at 6 months, 1, 2, and 3 years) using the Expanded Prostate Cancer Index …

Objectives Primary To compare the rates of unfavorable clinical outcomes in the two arms.Secondary To compare rates of major surgical morbidity and/or mortality between …

Inclusion Criteria Pre-Registration Eligibility Criteria: Patients must have pathologically confirmed pancreatic adenocarcinoma.Received 4-6 months of induction chemotherapy with either …

Objectives Primary Objective To compare overall survival in participants with newly diagnosed metastatic renal cell carcinoma who are randomized to receive immune checkpoint inhibitor …

Objectives Stage 1, Safety Run-In Primary Objective: Evaluate the safety and tolerability of tazemetostat in combination with lenalidomide + rituximab (R2) in subjects with …